SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001654954-20-003530
Filing Date
2020-03-30
Accepted
2020-03-30 17:23:24
Documents
81
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT azrx10k_dec312019.htm 10-K 1930498
2 CONSENTS OF EXPERTS AND COUNSEL ex23.htm EX-23 4118
3 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF ex31-1.htm EX-31.1 18763
4 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF ex31-2.htm EX-31 18957
5 CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE ex32-1.htm EX-32.1 12326
  Complete submission text file 0001654954-20-003530.txt   5087389

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT azrx-20191231.xml EX-101.INS 736335
7 XBRL TAXONOMY EXTENSION SCHEMA azrx-20191231.xsd EX-101.SCH 47831
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE azrx-20191231_cal.xml EX-101.CAL 51499
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE azrx-20191231_def.xml EX-101.DEF 130140
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE azrx-20191231_lab.xml EX-101.LAB 277558
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE azrx-20191231_pre.xml EX-101.PRE 241611
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37853 | Film No.: 20758487
SIC: 2834 Pharmaceutical Preparations